hVIVO plc has announced that its German subsidiary, CRS, has landed more than £5 million in new contracts since September, driven in large part by two returning mid-sized German pharmaceutical clients.
The early-phase clinical trial service agreements span a wide range of therapeutic areas — including cardiometabolic, dermatology, infectious disease, renal impairment, and oncology — with studies set to begin later this year and into the first half of 2026. Most of the associated revenue is expected to be recognised in 2026.
hVIVO said the contracts showcase strong cross-selling synergies with Venn Life Sciences, which supports CRS in delivering the projects. The company also highlighted rising proposal-to-contract conversion rates and ongoing operational efficiencies, adding that CRS is on track to become earnings accretive in 2026.
Dr Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said: “Securing over £5 million in new contracts, including two mid-sized pharma clients, underscores our strong reputation and the strategic importance of CRS within the Group. These wins demonstrate the success of our integration strategy and the value we deliver through combined expertise across the hVIVO Group. CRS has seen an increased conversion rate of proposals to contracts year-to-date versus 2024 and with a robust sales pipeline and continued efficiency improvements, CRS remains on track to become earnings accretive in 2026.”
Professor Thomas Forst, Chief Medical Officer of hVIVO, said: “At CRS, we are committed to delivering high-quality clinical trial services that accelerate the development of safe and effective medicines for patients worldwide. These new studies span multiple therapeutic areas and showcase the depth of our expertise and the trust our clients place in us. By combining scientific excellence with operational efficiency, we continue to strengthen our position as a leading partner for early-phase clinical research.”
